Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00016558 | Oral cavity | OSCC | urogenital system development | 160/7305 | 338/18723 | 1.03e-03 | 5.31e-03 | 160 |
GO:000165514 | Oral cavity | NEOLP | urogenital system development | 58/2005 | 338/18723 | 1.97e-04 | 2.13e-03 | 58 |
GO:00032312 | Oral cavity | NEOLP | cardiac ventricle development | 27/2005 | 123/18723 | 2.14e-04 | 2.27e-03 | 27 |
GO:0060840 | Oral cavity | NEOLP | artery development | 23/2005 | 100/18723 | 3.00e-04 | 2.97e-03 | 23 |
GO:00032814 | Oral cavity | NEOLP | ventricular septum development | 17/2005 | 71/18723 | 1.10e-03 | 8.28e-03 | 17 |
GO:00032053 | Oral cavity | NEOLP | cardiac chamber development | 30/2005 | 161/18723 | 1.78e-03 | 1.22e-02 | 30 |
GO:00720017 | Oral cavity | NEOLP | renal system development | 47/2005 | 302/18723 | 5.60e-03 | 2.97e-02 | 47 |
GO:00032793 | Oral cavity | NEOLP | cardiac septum development | 20/2005 | 103/18723 | 6.01e-03 | 3.13e-02 | 20 |
GO:00018226 | Oral cavity | NEOLP | kidney development | 45/2005 | 293/18723 | 8.36e-03 | 4.08e-02 | 45 |
GO:00016557 | Prostate | BPH | urogenital system development | 88/3107 | 338/18723 | 6.05e-06 | 8.83e-05 | 88 |
GO:00720016 | Prostate | BPH | renal system development | 76/3107 | 302/18723 | 8.55e-05 | 8.09e-04 | 76 |
GO:00018225 | Prostate | BPH | kidney development | 74/3107 | 293/18723 | 9.31e-05 | 8.76e-04 | 74 |
GO:00032813 | Prostate | BPH | ventricular septum development | 23/3107 | 71/18723 | 7.95e-04 | 5.21e-03 | 23 |
GO:0003231 | Prostate | BPH | cardiac ventricle development | 34/3107 | 123/18723 | 1.37e-03 | 8.20e-03 | 34 |
GO:00032792 | Prostate | BPH | cardiac septum development | 29/3107 | 103/18723 | 2.20e-03 | 1.22e-02 | 29 |
GO:00032052 | Prostate | BPH | cardiac chamber development | 41/3107 | 161/18723 | 2.63e-03 | 1.41e-02 | 41 |
GO:000165513 | Prostate | Tumor | urogenital system development | 90/3246 | 338/18723 | 1.08e-05 | 1.56e-04 | 90 |
GO:000182213 | Prostate | Tumor | kidney development | 74/3246 | 293/18723 | 3.68e-04 | 2.87e-03 | 74 |
GO:007200113 | Prostate | Tumor | renal system development | 75/3246 | 302/18723 | 5.74e-04 | 4.13e-03 | 75 |
GO:00032311 | Prostate | Tumor | cardiac ventricle development | 36/3246 | 123/18723 | 7.31e-04 | 5.08e-03 | 36 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CNTRL | SNV | Missense_Mutation | novel | c.3492N>A | p.Asp1164Glu | p.D1164E | Q7Z7A1 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
CNTRL | insertion | In_Frame_Ins | novel | c.5405_5406insCAAAATAGATTTTAAAAAAAT | p.Lys1802delinsAsnLysIleAspPheLysLysMet | p.K1802delinsNKIDFKKM | Q7Z7A1 | protein_coding | | | TCGA-A5-A0R9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CNTRL | insertion | Nonsense_Mutation | novel | c.6906_6907insACATAGCCATTCCCCCCACATAAATGTAAC | p.Ser2302_Gln2303insThrTerProPheProProHisLysCysAsn | p.S2302_Q2303insT*PFPPHKCN | Q7Z7A1 | protein_coding | | | TCGA-B5-A11V-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CNTRL | insertion | Frame_Shift_Ins | novel | c.4764_4764+1insGCAAGGA | p.Val1589AlafsTer20 | p.V1589Afs*20 | Q7Z7A1 | protein_coding | | | TCGA-D1-A0ZU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
CNTRL | insertion | Frame_Shift_Ins | novel | c.3891_3892insC | p.Asn1300GlnfsTer18 | p.N1300Qfs*18 | Q7Z7A1 | protein_coding | | | TCGA-DF-A2KY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
CNTRL | SNV | Missense_Mutation | rs151059757 | c.6706G>A | p.Ala2236Thr | p.A2236T | Q7Z7A1 | protein_coding | tolerated(0.05) | possibly_damaging(0.727) | TCGA-G3-A3CJ-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Targeted Molecular therapy | sorafenib | PD |
CNTRL | SNV | Missense_Mutation | | c.5057T>C | p.Val1686Ala | p.V1686A | Q7Z7A1 | protein_coding | tolerated(0.75) | benign(0.039) | TCGA-G3-A3CK-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CNTRL | SNV | Missense_Mutation | | c.6877G>A | p.Ala2293Thr | p.A2293T | Q7Z7A1 | protein_coding | tolerated(0.67) | benign(0) | TCGA-G3-A5SL-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CNTRL | SNV | Missense_Mutation | novel | c.5900N>C | p.Ser1967Thr | p.S1967T | Q7Z7A1 | protein_coding | tolerated(0.43) | benign(0.046) | TCGA-G3-AAUZ-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CNTRL | SNV | Missense_Mutation | | c.2094G>T | p.Gln698His | p.Q698H | Q7Z7A1 | protein_coding | deleterious(0.03) | benign(0.007) | TCGA-44-8120-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |